March 2012 Br J Cardiol 2012;19(Suppl 1):s1-s16
This supplement is a report from the inaugural meeting of the Cardiometabolic Forum, jointly organised by the British Journal of Cardiology and HEART UK – The Cholesterol Charity. The meeting was held at the Royal Pharmaceutical Society, London, on 24th November 2011. Meeting chairs were Dr Dermot Neely (Royal Victoria Infirmary, Newcastle upon Tyne) for HEART UK, and Dr Henry Purcell (Royal Brompton Hospital, London, and Editor) for BJC. We hope this supplement will provide readers with an independent overview on recent developments in our knowledge of cholesterol metabolism and its implications for clinical practice. Speakers Dermot Neely
March 2012 Br J Cardiol 2012;19(Suppl 1):s1-s16 doi:10.5837/bjc.2012.s02
Dermot Neely
Abnormalities in plasma lipoprotein concentrations are found in seven of out every 10 patients with premature coronary disease, with a familial disorder in more than half of these cases, highlighting the importance of accurate diagnosis and scope for early treatment of affected families.1 Clinical assessment, incorporating review of phenotypic features, personal and family history, physical signs and laboratory tests, is fundamental to diagnosis. Table 1. Key tests to exclude secondary causes of dyslipidaemia In the first instance, it is important to exclude secondary causes of dyslipidaemia. Diabetes mellitus, untreated hypothyroidism, neph
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits